** Shares of drug developer Cytokinetics CYTK.O rise ~3% to $36.24 premarket
** Co reported Q2 revenue of $66.8 million , compared with $0.2 million a year ago, helped by $52.4 million payment related to co's licensing deal for experimental heart disease drug, aficamten, in Japan with Germany's Bayer BAYGn.DE
** Co says it is on track for meeting with U.S. FDA in September ahead of potential U.S. approval of aficamten to treat obstructive hypertrophic cardiomyopathy (oCHM)
** There is "truly palpable excitement and anticipation" for launch of aficamten in early 2026 following potential FDA approval by December 26, H.C.Wainwright analysts say
** oCHM is a condition that makes heart muscles stiff and can cause cardiac arrest
** As of June 30, co had ~$1.0 billion in cash, cash equivalents and investments, CYTK says
** Up to last close, stock down 25% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。